^
    Back
    Association details:
    Biomarker:MYC mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:fimepinostat (CUDC-907) (PI3K inhibitor, HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Br J Haematol
    Title:

    Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses

    Published date:
    08/02/2021
    Excerpt:
    Prolonged durations of response were achieved by patients with MYC-altered R/R DLBCL/HGBL treated with single-agent fimepinostat,
    DOI:
    10.1111/bjh.17730